30 completed, 8 recruiting, 8 terminated, 7 withdrawn. 14 Phase 2, 9 Early Phase 1, 9 Phase 1, 9 Phase 3, 8 Not applicable.
Follow Feraheme: new trials by email Literature Review of Feraheme trials Research Report on Feraheme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nanozymes in Endodontics Nanozyme treatment, Control (Standard treatment) - Apical Periodontitis, Endodontic Disease | Phase 4 | Enrolling by invitation | University of Pennsylvania | 72 | 2026-08-24 | 2026-10-13 |
| Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging - Glioblastoma | Phase 3 | Recruiting | Jonsson Comprehensive Cancer Center | 15 | 2025-10-27 | 2026-03-10 |
| Virtual Histology of the Bladder Wall for Bladder Cancer Staging Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM) - Urinary Bladder Neoplasms | Early Phase 1 | Recruiting | Jodi Maranchie | 42 | 2025-05-23 | 2025-12-17 |
| Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy Ferumoxytol - Epilepsy, Temporal Lobe | Phase 2 | Recruiting | University of Alberta | 50 | 2025-05-01 | 2026-05-08 |
| Calculating Wall Shear Stress in Infant Pulmonary Veins Ferumoxytol - Pulmonary Vein Stenosis | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 20 | 2024-09-30 | 2026-08-05 |
| Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay Ferumoxytol, Gadobutrol - IC - Interstitial Cystitis | Completed | Christopher J Chermansky, MD | 7 | 2023-03-29 | 2026-07-10 | |
| A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Bryan Allen | 16 | 2023-02-28 | 2026-07-20 |
| Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection - Prematurity, Iron-deficiency | Phase 2 | Recruiting | University of Washington | 120 | 2022-11-27 | 2026-05-26 |
| Novel Imaging Markers in SPMS Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine - Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive | Early Phase 1 | Completed | University of Utah | 11 | 2022-06-01 | 2026-08-13 |
| Placental Lesions in Fetal Growth Restrictions Ferumoxytol infusion, MRI scan - Fetal Growth Retardation | Early Phase 1 | Completed | University of Wisconsin, Madison | 3 | 2021-04-15 | 2025-08-22 |
| Predicting Stroke Risk in ICAD With Novel MRI Feraheme - Intracranial Atherosclerosis | Phase 4 | Withdrawn | Northwestern University | 2020-09-01 | 2026-08-06 | |
| A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment Iron oxide nanoparticles treatment Ferumoxytol/H2O2, NaOCl, NaCl - Apical Periodontitis, Pulp Disease, Dental | Phase 4 | Completed | University of Pennsylvania | 44 | 2020-07-13 | 2024-08-28 |
| IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding Ferumoxytol, Ferrous Sulfate - Anemia, Iron Deficiency, Heavy Menstrual Bleeding | Phase 4 | Unknown | Thomas Jefferson University | 76 | 2020-02-14 | 2023-11-21 |
| A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects ferumoxytol, Iron sucrose - Iron Deficiency Anemia | Phase 3 | Recruiting | AMAG Pharmaceuticals, Inc. | 75 | 2019-09-18 | 2026-04-17 |
| Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Ferumoxytol - Pulmonary Embolism | Phase 1 | Completed | Brigham and Women's Hospital | 1 | 2018-09-21 | 2022-07-26 |
| A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Ferumoxytol, Iron sucrose - Chronic Kidney Disease; Iron Deficiency Anemia | Phase 3 | Recruiting | AMAG Pharmaceuticals, Inc. | 129 | 2018-08-13 | 2026-04-17 |
| Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model Ferumoxytol/Hydrogen peroxide, Hydrogen Peroxide, Water - Dental Caries | Early Phase 1 | Completed | University of Pennsylvania | 16 | 2018-06-07 | 2018-09-19 |
| Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer Ferumoxytol, Magnetic Resonance Imaging - Stage IIB Esophageal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7 | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2018-04-27 | 2021-09-16 | |
| Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol - Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7 | Early Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2018-04-27 | 2021-09-10 |
| Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging - Glioblastoma | Phase 2 | Terminated | OHSU Knight Cancer Institute | 52 | 2017-12-20 | 2025-09-09 |
Showing 20 of 58. Sign in to see all of them.
Anemia, Iron-Deficiency (14) · Anemia (5) · Brain Neoplasms (5) · Renal Insufficiency, Chronic (5) · Glioblastoma (4) · AIDS Dementia Complex (2) · Dental Pulp Diseases (2) · Esophageal Neoplasms (2) · Intracranial Arteriosclerosis (2) · Iron Deficiencies (2) · Multiple Sclerosis (2) · Periapical Periodontitis (2) · Stroke (2) · Urinary Bladder Neoplasms (2) · Bone Neoplasms (1)
OHSU Knight Cancer Institute (12) · AMAG Pharmaceuticals, Inc. (9) · Stanford University (3) · University of Pennsylvania (3) · Brigham and Women's Hospital (2) · Michael Iv (2) · National Cancer Institute (NCI) (2) · Beau Nakamoto (1) · Bryan Allen (1) · Children's Hospital of Philadelphia (1) · Christopher J Chermansky, MD (1) · Dana-Farber Cancer Institute (1) · Danish Headache Center (1) · Dialysis Clinic, Inc. (1) · Georges Ouellet (1)
United States (50) · Canada (7) · Poland (7) · Hungary (5) · Latvia (4) · Lithuania (4) · India (3) · United Kingdom (3) · Germany (2) · Australia (1) · Belgium (1) · Denmark (1) · France (1) · Italy (1) · Mexico (1)
Edward Neuwelt (4) · Alexander Guimaraes (3) · Edward A Neuwelt (2) · Adam de Havenon, MD (1) · Andrew M Siedlecki, MD (1) · Beau K Nakamoto, MD, PhD (1) · Beau Nakamoto, MD, PhD (1) · Bekir Karabucak, DMD, MS (1) · Brian Rutt, PhD (1) · Christopher Chermansky, MD (1) · Dinesh Shah, MD (1) · Domenick Zero, Ph.D (1) · Donald Gross, MD (1) · Edward A Neuwelt, MD (1) · Edward Neuwelt, MD (1)
PMID 24458078, PMID 24559803, PMID 26786296, PMID 28372549, PMID 29248659, PMID 30518682, PMID 30802204, PMID 31104505, PMID 32368961, PMID 34870211, PMID 36999999, PMID 37010988, PMID 41430711
R01CA137488 (3), 2009 (1), K08CA237809 (1), K08EB012859 (1), KL2TR001882 (1), P01AI054904 (1), P30CA069533 (1), P30CA124435 (1), R01CA269231 (1), R01HD107003 (1), R01NS034608 (1), R21CA270742 (1), R21NS087951 (1), R44DK108397 (1), U01CA278923 (1)